Pacira BioSciences Inc (NASDAQ: PCRX) stock suffered a major decline of -47.7% on 8/9/24. The shares closed at $11.70. Moreover, exceptionally high trading volume at 272% of normal accompanied the decline. Relative to the market the stock has been extremely weak over the last nine months and has declined -43.6% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, PCRX is expected to continue to be an important Value Builder.
Pacira BioSciences has a current Value Trend Rating of C (High Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Pacira BioSciences has a very high Appreciation Score of 93 but a poor Power Rating of 27, producing the High Neutral Value Trend Rating.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment